Patents Assigned to TeneoBio, Inc.
  • Anti-BCMA heavy chain-only antibodies
    Patent number: 11970540
    Abstract: Anti-BCMA heavy chain-only antibodies (UniAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: June 20, 2018
    Date of Patent: April 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Shelley Force Aldred, Katherine Harris, Wim van Schooten
  • ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS
    Publication number: 20240091264
    Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: November 30, 2023
    Publication date: March 21, 2024
    Applicants: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, TeneoBio, Inc.
    Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten
  • Multispecific heavy chain antibodies binding to CD22 and CD3
    Patent number: 11905326
    Abstract: Multispecific, human heavy chain antibodies (e.g., UniAbs™) binding to CD22 and CD3 are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat disorders that are characterized by the expression of CD22.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: February 20, 2024
    Assignee: TeneoBio, Inc.
    Inventors: Nathan Trinklein, Udaya Rangaswamy, Suhasini Iyer, Kirthana Prabhakar, Harshad Ugamraj
  • Agonistic anti-IL-2R antibodies and methods of use
    Patent number: 11884735
    Abstract: Anti-IL2R (e.g., anti-IL2RB, anti-IL2RG, anti-IL2RB/G) antibodies are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and use of such antibodies and compositions in the treatment of diseases and disorders that are mediated by the IL2/IL2R signaling pathway.
    Type: Grant
    Filed: February 3, 2023
    Date of Patent: January 30, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Nathan Trinklein, Katherine Harris, Kyle Lorentsen, Harbani Kaur Malik Chaudhry, Kaitlyn Loughlin
  • Heavy chain antibodies binding to CD22
    Patent number: 11873336
    Abstract: Anti-CD22 heavy chain antibodies (e.g., UniAbs™) are disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B cell disorders that are characterized by the expression of CD22.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 16, 2024
    Assignee: TENEOBIO, INC.
    Inventors: Shelley Force Aldred, Wim van Schooten, Heather Anne N. Ogana, Laura Marie Davison, Katherine Harris, Udaya Rangaswamy, Nathan D. Trinklein
  • CD3 binding antibodies
    Patent number: 11613572
    Abstract: The present invention relates to novel human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: March 28, 2023
    Assignee: TeneoBio, Inc.
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • CD3 binding antibodies
    Patent number: 11505606
    Abstract: The present invention relates to human CD3 antigen-binding polypeptides and their preparation and use in the treatment and/or diagnosis of various diseases, and also relates to bispecific antibody molecules capable of activating immune effector cells and their use in diagnosis and/or treatment of various diseases.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: November 22, 2022
    Assignee: TeneoBio, Inc.
    Inventors: Nathan Trinklein, Wim van Schooten, Shelley Force Aldred, Katherine Harris, Duy Pham
  • Anti-BCMA heavy chain-only antibodies
    Patent number: 11434299
    Abstract: Anti-BCMA heavy chain-only antibodies (HCAb) and disclosed, along with methods of making such antibodies, compositions, including pharmaceutical compositions, comprising such antibodies, and their use to treat B-cell disorders characterized by the expression of BCMA.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: September 6, 2022
    Assignee: TeneoBio, Inc.
    Inventors: Shelley Force Aldred, Nathan Trinklein, Katherine E. Harris, Kevin Dang, Wim van Schooten
  • ANTI-B-CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTORS WITH HUMAN DOMAINS
    Publication number: 20200138865
    Abstract: Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.
    Type: Application
    Filed: June 28, 2018
    Publication date: May 7, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, TeneoBio, Inc.
    Inventors: James N. Kochenderfer, Norris Lam, Nathan Trinklein, Katherine E. Harris, Shelley Force Aldred, Wim Van Schooten